---
title: "Taysha Gene Therapies President, Head of R&D Sukumar Nagendran disposes of 200,000 common shares for $1.25 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292362092.md"
description: "Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, sold 200,000 common shares on July 10, 2026. The transaction occurred at a weighted-average price of $6.24 per share, totaling approximately $1.25 million. Following the sale, Nagendran holds 936,410 shares directly."
datetime: "2026-07-10T22:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292362092.md)
  - [en](https://longbridge.com/en/news/292362092.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292362092.md)
---

# Taysha Gene Therapies President, Head of R&D Sukumar Nagendran disposes of 200,000 common shares for $1.25 million

-   Taysha Gene Therapies President and Head of R&D Sukumar Nagendran sold 200,000 common shares on July 10, 2026. \* Sale priced at USD 6.24 per share on a weighted-average basis. \* Post-transaction holding totaled 936,410 shares, held directly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001665124-26-000013), on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome](https://longbridge.com/en/news/293788160.md)
- [Taysha Gene Therapies posts REVEAL Part A Phase 1/2 TSHA-102 Rett syndrome trial presentation](https://longbridge.com/en/news/291157030.md)
- [SUI price prediction 2026-2032: Is SUI a good investment?](https://longbridge.com/en/news/293965949.md)
- [TIP buys 229,863 shares at average price of EUR 9.34 under buyback program](https://longbridge.com/en/news/293944238.md)
- [Insider Selling: ACRES Commercial Realty (NYSE:ACR) Major Shareholder Sells 1,389 Shares of Stock](https://longbridge.com/en/news/294282341.md)